mitoxantrone has been researched along with Bone Marrow Diseases in 25 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Bone Marrow Diseases: Diseases involving the BONE MARROW.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Based upon the hypothesis that dipyridamole would potentiate the cytotoxicity of mitoxantrone and the combination of 5-fluorouracil (5-FU) and leukovorin, we performed a phase I/II trial of the combination of dipyridamole, 5-FU, leukovorin, and mitoxantrone in patients with metastatic breast cancer." | 9.07 | Phase I/II trial of dipyridamole, 5-fluorouracil, leukovorin, and mitoxantrone in metastatic breast cancer. ( Budd, GT; Bukowski, RM; Herzog, P, 1994) |
| "We conducted a dose-finding study of mitoxantrone (MITO) in combination with high-dose cyclophosphamide, carmustine (BCNU), and etoposide (CBV) in refractory lymphoma undergoing autologous bone marrow transplantation (ABMT)." | 9.07 | Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation. ( Attal, M; Canal, P; Chatelut, E; Dezeuze, A; Huguet, F; Laurent, G; Payen, C; Pris, J; Schlaifer, D, 1994) |
| "Thirty-one patients with ovarian cancer who had failed chemotherapy were treated, 24 at the MTD." | 6.68 | A phase I-II study of high-dose melphalan, mitoxantrone and carboplatin with peripheral blood stem cell support in patients with advanced ovarian or breast carcinoma. ( Baldwin, P; Buckner, CD; Greco, FA; Hainsworth, JD; Lewis, M; Schwartzberg, L; Weaver, CH; West, WH; Wittlin, F; Zhen, B, 1997) |
| "Mitoxantrone was well tolerated, myelosuppression being the dose-limiting toxicity." | 5.27 | Mitoxantrone for the treatment of advanced breast cancer: single-agent therapy in previously untreated patients. ( Coleman, RE; Cornbleet, MA; McDonald, M; Mouridsen, HT; Rainer, H; Rubens, RD; Smith, IE; Smyth, JF; Stuart-Harris, RC; van Oosterom, AT, 1984) |
| "Based upon the hypothesis that dipyridamole would potentiate the cytotoxicity of mitoxantrone and the combination of 5-fluorouracil (5-FU) and leukovorin, we performed a phase I/II trial of the combination of dipyridamole, 5-FU, leukovorin, and mitoxantrone in patients with metastatic breast cancer." | 5.07 | Phase I/II trial of dipyridamole, 5-fluorouracil, leukovorin, and mitoxantrone in metastatic breast cancer. ( Budd, GT; Bukowski, RM; Herzog, P, 1994) |
| "We conducted a dose-finding study of mitoxantrone (MITO) in combination with high-dose cyclophosphamide, carmustine (BCNU), and etoposide (CBV) in refractory lymphoma undergoing autologous bone marrow transplantation (ABMT)." | 5.07 | Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation. ( Attal, M; Canal, P; Chatelut, E; Dezeuze, A; Huguet, F; Laurent, G; Payen, C; Pris, J; Schlaifer, D, 1994) |
| "Among 35 patients with relapsed or refractory acute myelogenous leukemia (AML) who received salvage chemotherapy, 28 were treated with mitoxantrone (7." | 3.68 | Mitoxantrone and high-dose etoposide for patients with relapsed or refractory acute leukemia. ( Beran, M; Estey, E; Kantarjian, H; Keating, M; Koller, C; McCredie, K; O'Brien, S, 1991) |
| " No toxic deaths have occurred." | 2.69 | Etoposide, mitoxantrone and prednisone: a salvage regimen with low toxicity for refractory or relapsed non-Hodgkin's lymphoma. ( Budel, L; Doorduijn, JK; Löwenberg, B; Sonneveld, P; Spruit, P; van Der Holt, B; van't Veer, M, 2000) |
| "Thirty-one patients with ovarian cancer who had failed chemotherapy were treated, 24 at the MTD." | 2.68 | A phase I-II study of high-dose melphalan, mitoxantrone and carboplatin with peripheral blood stem cell support in patients with advanced ovarian or breast carcinoma. ( Baldwin, P; Buckner, CD; Greco, FA; Hainsworth, JD; Lewis, M; Schwartzberg, L; Weaver, CH; West, WH; Wittlin, F; Zhen, B, 1997) |
| " However, in vitro data demonstrate a steep dose-response curve to a variety of agents, most notably mitoxantrone." | 2.67 | Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide, and autologous bone marrow rescue: high response rate for refractory ovarian carcinoma. ( Alberts, DS; Dolan, JR; McCloskey, T; McKenzie, RS; Rad, N; Sosman, JA; Stiff, PJ, 1994) |
| "Mitoxantrone was well tolerated, myelosuppression being the dose-limiting toxicity." | 1.27 | Mitoxantrone for the treatment of advanced breast cancer: single-agent therapy in previously untreated patients. ( Coleman, RE; Cornbleet, MA; McDonald, M; Mouridsen, HT; Rainer, H; Rubens, RD; Smith, IE; Smyth, JF; Stuart-Harris, RC; van Oosterom, AT, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (16.00) | 18.7374 |
| 1990's | 15 (60.00) | 18.2507 |
| 2000's | 6 (24.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Janikova, A | 1 |
| Koristek, Z | 1 |
| Vinklarkova, J | 1 |
| Pavlik, T | 1 |
| Sticha, M | 1 |
| Navratil, M | 1 |
| Kral, Z | 1 |
| Vasova, I | 1 |
| Mayer, J | 1 |
| Schmitt, B | 1 |
| Wendtner, CM | 1 |
| Bergmann, M | 1 |
| Busch, R | 1 |
| Franke, A | 1 |
| Pasold, R | 1 |
| Schlag, R | 1 |
| Hopfinger, G | 1 |
| Hiddemann, W | 2 |
| Emmerich, B | 1 |
| Hallek, M | 1 |
| Osman, I | 1 |
| Akin, U | 1 |
| Ismet, A | 1 |
| Meral, B | 1 |
| Hamdi, A | 1 |
| Haluk, K | 1 |
| Boiardi, A | 1 |
| Bartolomei, M | 1 |
| Silvani, A | 1 |
| Eoli, M | 1 |
| Salmaggi, A | 1 |
| Lamperti, E | 1 |
| Milanesi, I | 1 |
| Botturi, A | 1 |
| Rocca, P | 1 |
| Bodei, L | 1 |
| Broggi, G | 1 |
| Paganelli, G | 1 |
| Cornbleet, MA | 1 |
| Stuart-Harris, RC | 1 |
| Smith, IE | 1 |
| Coleman, RE | 1 |
| Rubens, RD | 1 |
| McDonald, M | 1 |
| Mouridsen, HT | 1 |
| Rainer, H | 1 |
| van Oosterom, AT | 1 |
| Smyth, JF | 1 |
| Pedrazzoli, P | 1 |
| Zamagni, C | 1 |
| Martoni, A | 1 |
| Capotorto, AM | 1 |
| Da Prada, GA | 1 |
| Pavesi, L | 1 |
| Preti, P | 1 |
| Lelli, G | 1 |
| Pannuti, F | 1 |
| Robustelli della Cuna, G | 1 |
| Avilés, A | 1 |
| Díaz-Maqueo, JC | 1 |
| Talavera, A | 1 |
| Nambo, MJ | 1 |
| García, EL | 1 |
| Fuchsberger, P | 1 |
| Lakota, J | 1 |
| Budd, GT | 1 |
| Herzog, P | 1 |
| Bukowski, RM | 1 |
| Angós, JA | 1 |
| Gutiérrez, M | 1 |
| Moreno, JA | 1 |
| Aguado, MJ | 1 |
| Romero, MS | 1 |
| Attal, M | 1 |
| Canal, P | 1 |
| Schlaifer, D | 1 |
| Chatelut, E | 1 |
| Dezeuze, A | 1 |
| Huguet, F | 1 |
| Payen, C | 1 |
| Pris, J | 1 |
| Laurent, G | 1 |
| Stiff, PJ | 1 |
| McKenzie, RS | 1 |
| Alberts, DS | 1 |
| Sosman, JA | 1 |
| Dolan, JR | 1 |
| Rad, N | 1 |
| McCloskey, T | 1 |
| Chisesi, T | 1 |
| Haas, R | 1 |
| Moos, M | 1 |
| Möhle, R | 1 |
| Döhner, H | 1 |
| Witt, B | 1 |
| Goldschmidt, H | 1 |
| Murea, S | 1 |
| Flentje, M | 1 |
| Wannenmacher, M | 1 |
| Hunstein, W | 1 |
| Meisenberg, BR | 1 |
| Miller, WE | 1 |
| McMillan, R | 1 |
| Weaver, CH | 1 |
| Greco, FA | 1 |
| Hainsworth, JD | 1 |
| Zhen, B | 1 |
| Baldwin, P | 1 |
| Wittlin, F | 1 |
| Lewis, M | 1 |
| West, WH | 1 |
| Schwartzberg, L | 1 |
| Buckner, CD | 1 |
| Kurbacher, CM | 1 |
| Bruckner, HW | 1 |
| Cree, IA | 1 |
| Kurbacher, JA | 1 |
| Wilhelm, L | 1 |
| Pöch, G | 1 |
| Indefrei, D | 1 |
| Mallmann, P | 1 |
| Andreotti, PE | 1 |
| Doorduijn, JK | 1 |
| Spruit, P | 1 |
| van Der Holt, B | 1 |
| van't Veer, M | 1 |
| Budel, L | 1 |
| Löwenberg, B | 1 |
| Sonneveld, P | 1 |
| Johnston, LJ | 1 |
| Stockerl-Goldstein, KE | 1 |
| Hu, WW | 1 |
| Negrin, RS | 1 |
| Hoppe, RT | 1 |
| Blume, KG | 1 |
| Horning, SJ | 1 |
| Robak, T | 1 |
| Góra-Tybor, J | 1 |
| Lech-Marańda, E | 1 |
| Błoński, JZ | 1 |
| Kasznicki, M | 1 |
| O'Brien, S | 1 |
| Kantarjian, H | 1 |
| Estey, E | 1 |
| Koller, C | 1 |
| Beran, M | 1 |
| McCredie, K | 1 |
| Keating, M | 1 |
| Ehninger, G | 1 |
| Fackler-Schwalbe, E | 1 |
| Freund, M | 1 |
| Heil, G | 1 |
| Henke, M | 1 |
| Hoelzer, D | 1 |
| Hoffmann, R | 1 |
| Kurrle, E | 1 |
| Link, H | 1 |
| Lösch, A | 1 |
| Morton, AR | 1 |
| Anderson, H | 1 |
| Howell, A | 1 |
| Powles, TI | 1 |
| Ashley, S | 1 |
| Kreutzmann, H | 1 |
| Straif, K | 1 |
| Ludwig, WD | 1 |
| Mertelsmann, R | 1 |
| Donhuijsen-Ant, R | 1 |
| Lengfelder, E | 1 |
| Arlin, Z | 1 |
| Büchner, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Trial of High-dose Topotecan in Association With Carboplatin, With Peripheral Blood Stem Cell Support in Patients With First Relapsed Ovarian Carcinoma Without Platinum-treatment Since 6-12 Months[NCT01177501] | Phase 1 | 3 participants (Actual) | Interventional | 2009-04-30 | Terminated (stopped due to choice of the principal investigator) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for mitoxantrone and Bone Marrow Diseases
| Article | Year |
|---|---|
Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia.
Topics: Adolescent; Adult; Aged; Alemtuzumab; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodie | 2002 |
14 trials available for mitoxantrone and Bone Marrow Diseases
| Article | Year |
|---|---|
Mitoxantrone and cytosine arabinoside in previously untreated adult patients with acute non-lymphocytic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cytar | 1996 |
Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow Diseases; Brain Neoplasms; Chemotherapy, | 2005 |
Dose intensification of chemotherapy in advanced breast cancer: a feasibility phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Breast Neoplasms; | 1994 |
Effect of granulocyte colony-stimulating factor in patients with diffuse large cell lymphoma treated with intensive chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Dise | 1994 |
Phase I/II trial of dipyridamole, 5-fluorouracil, leukovorin, and mitoxantrone in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Breast Neoplasms; | 1994 |
Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplanta | 1994 |
Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide, and autologous bone marrow rescue: high response rate for refractory ovarian carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplanta | 1994 |
The rationale of therapy with mitoxantrone in non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Co-operative Study Group, (NHLCSG) Italy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cyclophosphamide; | 1993 |
High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bone Marrow Diseases; Carmu | 1996 |
A phase I-II study of high-dose melphalan, mitoxantrone and carboplatin with peripheral blood stem cell support in patients with advanced ovarian or breast carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Breast Neoplasms; Carbo | 1997 |
Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone | 1997 |
Etoposide, mitoxantrone and prednisone: a salvage regimen with low toxicity for refractory or relapsed non-Hodgkin's lymphoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Ma | 2000 |
Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cladribine; Cyclophospha | 2001 |
Combination of mitoxantrone and etoposide in patients aged over 60 years with untreated acute myelogenous leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Etoposide; Humans; Leuke | 1990 |
10 other studies available for mitoxantrone and Bone Marrow Diseases
| Article | Year |
|---|---|
Efficacious but insidious: a retrospective analysis of fludarabine-induced myelotoxicity using long-term culture-initiating cells in 100 follicular lymphoma patients.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antine | 2009 |
Mitoxantrone for the treatment of advanced breast cancer: single-agent therapy in previously untreated patients.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Bone Marrow Diseases; Breast Neoplasms; Electroc | 1984 |
High-dose chemotherapy and autologous peripheral stem cell transplantation in patients with relapsing malignant lymphomas--first experience in the Slovak Republic.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carboplatin; Carmustine; Cyclo | 1995 |
[Combined therapy with mitoxantrone and cytosine arabinoside as a first-line treatment in ANLL: preliminary results].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cytarabine; Drug Evaluation; H | 1993 |
Mobilized peripheral blood progenitor cells (PBPC) in support of tandem cycles of high-dose chemotherapy (HDC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Trans | 1996 |
Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma.
Topics: Acute Kidney Injury; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bo | 2000 |
Mitoxantrone and high-dose etoposide for patients with relapsed or refractory acute leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Etoposide; Female | 1991 |
Myelotoxicity of methotrexate, mitozantrone, and mitomycin C.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Breast Neoplasms; Female | 1987 |
Myelosuppression after methotrexate, mitozantrone, and mitomycin C combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Humans; Methotrexate; Mitomyci | 1987 |
High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cytarabine; | 1987 |